Introduction
The incidence of acute myeloid leukemia (AML) increases with age. Elderly patients have gradually become the main individuals affected by AML due to an ageing population. AML patients in developed countries are diagnosed at an average age of 71 years (1) . Typically, the threshold for leukemia in elderly patients is considered to be between 55 and 65 years old (2) . The prognosis in patients <50 years old has been found to be significantly different from that in patients between 50 and 65 years old (3) . Compared with younger patients, elderly patients with AML exhibit more karyotypes associated with a poor prognosis (4,5), higher expression rates of gene mutations associated with drug resistance (6) , and are more frequently secondary to myelodysplastic syndrome (7, 8) . Therefore, the prognosis of patients with AML declines with age. The median overall survival (OS) time of AML patients aged 16-55, 56-65, 66-75 and ≥75 years has been recorded as 1,119, 359, 180 and 80 days, respectively (1) .
In 2010, Guo et al (9) first reported that the 2-year OS rate in elderly patients with AML increased from 11 to 39% with fractional infusion of small amounts of allogeneic hematopoietic stem cells (microtransplantation) following chemotherapy. Microtransplantation was reported to have anti-leukemic effects and promoted hematopoietic recovery (9, 10) . Although the prognosis in elderly patients with AML has been significantly improved by microtransplantation combined with chemotherapy, it remains inferior compared with that in young patients. For AML patients <65 years old, when microtransplantation was added to chemotherapy, the 6-year OS rate for low-and medium-risk patients reached 89.5 and 65.2%, respectively (10) . These results indicate that there is room for improvement in the efficacy of this treatment paradigm in elderly patients with AML. To accomplish this, maintenance therapy by low-dose chemotherapeutic treatment combined with microtransplantation was performed in three elderly patients (>55 years old) with leukemia, and the findings are reported in the present study. Recombinant human granulocyte colony-stimulating factor (Kirin-Sankyo Co., Ltd., Tokyo, Japan) was subcutaneously injected at a dose of 5 µg/kg/day to mobilize the peripheral blood stem cells daily for 5 days. The peripheral blood stem cells were collected on days 5 and 6 with CS-3000 plus blood cell separators (Baxter Healthcare Ltd., Berkshire, UK). Table I , all patients received maintenance treatment following complete response (CR) induction and intensified consolidation chemotherapy. For the patients who received chemotherapy, donor stem cell infusion was performed at 36 h post-chemotherapy. In total, 2-4x10 8 /kg mononuclear cells were infused each time. Single-dose 5 mg dexamethasone was used to prevent allergy. Other immunosuppressants for the prevention of graft versus host disease (GVHD) were not used.
Maintenance therapy regimes. As detailed in
Evaluation of efficacy and adverse reactions. CR was defined by the presence of <5% bone marrow blasts, no extramedullary infiltration of leukemic cells and normal results in the peripheral hemocyte analysis. The follow-up deadline was April 30, 2014. Disease-free survival (DFS) was defined as the duration from CR induction to the follow-up deadline.
Results
General data. The three patients were aged between 58 and 62 years old and consisted of two males and one female. The detailed diagnosis and treatment processes of the three cases are shown in Table I .
Treatment efficacy. The detailed treatment process of the patient with AMLL has previously been reported (11) , and the patient was further followed in the present study. In brief, subsequent to autologous stem cell transplantation and sequential allogeneic hematopoietic stem cell microtransplantation, the patient had achieved DFS for 27 months. The bone marrow WT1 levels in the patient decreased following microtransplantation and declined more significantly with an increased number of courses of microtransplantation (Fig. 1) . Upon reexamination in April 2014, the patient maintained the CR state.
Cases 2 and 3 were AML patients with intermediate-risk in chromosomal and molecular biological evaluations. The two patients achieved CR induction using a combined treatment paradigm of daunorubicin, arabinosylcytosine (Ara-C) and etoposide (also known as the DAE regimen). Following the DAE regimen treatment, medium-dose Ara-C ( Adverse effects. Of the 17 times that microtransplantation treatment was administered in the three patients, discomforts such as fever and diarrhea were not observed. A transient rash and pruritus occurred twice during transfusion and the patients recovered without treatment.
Discussion
For elderly AML patients aged 55-65 years, even intensive chemotherapy has been shown to only achieve an average OS time of 530 days, which is considerably shorter than the 2,546 days observed in patients <55 years old (1). For those patients with intermediate-risk AML, the average OS time is only 12 months (12). The prognosis of patients with AMLL is worse than that of elderly patients with AML, with a median survival time of only 9 months if chemotherapy only was recommended (13) . Of the three patients in the present study, one case with AMLL was treated by autologous transplantation followed by microtransplantation as maintenance therapy and two cases with intermediate-risk AML were treated and maintained by microtransplantation combined with chemotherapy. All three patients achieved a DFS time of >16 months (mean, 21 months), suggesting that maintenance with microtransplantation combined with chemotherapy could improve the prognosis in elderly patients with AML. These results were consistent with the results from the study by Guo et al (9, 10) . The study found that the 2 year OS and event free survival (EFS) rates in elderly patients with AML treated by chemotherapy combined with microtransplantation were increased significantly compared with those of patients treated by chemotherapy alone.
Typically, maintenance therapy is not recommended for patients with AML. In a study consisting of 789 AML patients aged 15-64 years, patients post-CR induction were randomly divided into a group administered four cycles of standard chemotherapy consolidation and a group administered maintenance after three cycles of standard chemotherapy consolidation. The results showed that there was no significant difference in the DFS and progression-free survival rates between the two groups, suggesting that patients who completed intensive consolidation may not benefit from maintenance therapy (14) . However, elderly patients with AML often cannot tolerate high-dose chemotherapy owing to their declining physical health. In a study of patients with AML aged 46-60 years, the increased intensity of consolidation treatment following CR induction reduced the relapse rate, but the benefits were counteracted by increased treatment-related mortality and the overall survival rate was not improved, compared with the conventional consolidation group (15) . Buchner et al (16) randomly divided 832 AML patients who were >16 years of age into an intensive treatment group and a maintenance treatment group. The Ara-c dose in the consolidation program used in the patients >60 years of age was adjusted from 3 to 1 g/m 2 , and the results showed that the patients >60 years of age benefited from the maintenance therapy. Ferrero et al (17) also found that maintenance therapy for patients with AML who were unsuitable for chemotherapy could reduce the recurrence rate and improve the long-term survival rate. Therefore, elderly patients with AML may be more dependent on maintenance therapy to reduce the incidence of relapses and improve the prognosis, as the low intensity of chemotherapy during consolidation treatment may not be high enough to eradicate residual leukemia.
Lowenberg et al (18) administered maintenance therapy by low-dose Ara-C in elderly AML patients. The results showed that the DFS rate of the patients was significantly /1x10 4 ABL copy number) pior to microtransplantation. Following microtransplantation, the WT1 levels gradually decreased to the normal range.
improved, but that the OS rate was not, as the non-relapse mortality rate in the maintenance group was increased. Microtransplantation of allogeneic hematopoietic stem cells may not only promote hematopoietic recovery and improve the tolerance to chemotherapy, but it may also activate specific anti-leukemia effects in elderly patients (9, 10) . We hypothesized that microtransplantation may be more feasible and effective in maintenance therapy for elderly patients with AML. Treatment-related mortality was not observed in the three patients who received the maintenance therapy of microtransplantation combined with low-dose chemotherapy following intensive therapy in the present study. WT1 could be used as an indicator of residual disease, and an increase in WT1 level may indicate early relapse (19) . In the present study, during the maintenance therapy, dynamic changes in the WT1 level were monitored in one patient. The results showed that the WT1 level gradually declined with an increasing number of microtransplantations, confirming that maintenance therapy with microtransplantation could be effective in eradicating residual disease. During the course of maintenance therapy using microtransplantation, no patient suffered from GVHD, suggesting that microtransplantation was safe to use as maintenance therapy.
